Clinical interchangeability of programmed cell death-ligand 1 (PD-L1) immunohistochemistry (IHC) assays for the treatment of first-line (1L) non-small cell lung cancer (NSCLC) with cemiplimab

Category Primary study
JournalAnnals of Oncology
Year 2022
This article has no abstract
Epistemonikos ID: ffe22d965e7c65dacc2fc29caca37e263f3091e1
First added on: Feb 15, 2025